Viewing Study NCT05607550

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:50 PM
Ignite Modification Date: 2026-02-24 @ 1:16 AM
Study NCT ID: NCT05607550
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-06-22
First Post: 2022-10-31
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Sponsor: ArriVent BioPharma, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Non-Small Cell Lung Cancer View
None Advanced Non-Small Cell Lung Cancer View
None EGFR Exon 20 Mutations View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Non-Small Cell Lung Cancer (NSCLC) View
None Exon 20 View
None Furmonertinib View
None Firmonertinib View
None AST2818 View
None FURMO-004 View
None Drug-Therapy View